IP Library Patent Application 10990275
Patent Application
App. No. 10/990,275

Methods and compositions for diagnosing and monitoring transplant rejection

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/990,275
Abstract

Methods of diagnosing or monitoring transplant rejection or cytomegalovirus infection in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection or cytomegalovirus infection and kits or systems containing the same are also described.

Claims (9)

1 - 35 . (canceled)

36 . A method of diagnosing or monitoring transplant rejection in a patient, comprising detecting the expression level of one or more genes in said patient to diagnose or monitor transplant rejection in said patient wherein said one or more genes comprise a nucleotide sequence selected from the group consisting of SEQ ID NO: 2127, SEQ ID NO: 2011, SEQ ID NO: 2762, SEQ ID NO: 4565, SEQ ID NO: 7295, SEQ ID NO: 5038, SEQ ID NO: 2421, SEQ ID NO: 3080, SEQ ID NO: 2347 and SEQ ID NO: 269.

37 . The method of claim 36 wherein said transplant rejection is cardiac transplant rejection.

38 . The method of claim 36 wherein said expression level is detected by measuring the RNA level expressed by said one or more genes.

39 . The method of claim 38 , further including isolating RNA from said patient prior to detecting said RNA level expressed by said one or more genes.

40 . The method of claim 38 wherein said RNA level is detected by PCR.

41 . The method of claim 38 wherein said RNA level is detected by hybridization.

42 . The method of claim 38 wherein said RNA level is detected by hybridization to an oligonucleotide.

43 . The method of claim 42 wherein said oligonucleotide comprises DNA, RNA, cDNA, PNA, genomic DNA, or synthetic oligonucleotides.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Aug 9, 2012
From: LEADER VENTURES, LLC
To: XDX, INC.
Reel/Frame 028757/0096 →
RELEASE OF SECURITY INTEREST Recorded Jan 20, 2011
From: TRIPLEPOINT CAPITAL LLC
To: XDX, INC.
Reel/Frame 025671/0583 →
SECURITY AGREEMENT Recorded Aug 31, 2009
From: XDX, INC.
To: LEADER VENTURES, LLC, AS AGENT
Reel/Frame 023163/0695 →
SECURITY AGREEMENT Recorded Aug 31, 2009
From: XDX, INC.
To: TRIPLEPOINT CAPITAL LLC
Reel/Frame 023163/0704 →
CHANGE OF NAME Recorded Oct 25, 2007
From: EXPRESSION DIAGNOSTICS, INC.
To: XDX, INC.
Reel/Frame 020018/0013 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2005
From: WOHLGEMUTH, JAY; FRY, KIRK; WOODWARD, ROBERT; LY, NGOC
To: EXPRESSION DIAGNOSTICS, INC. DBA XDX, INC.
Reel/Frame 016281/0047 →